Ligand Pharmaceuticals Inc. (LGND)

104.68
5.40 5.40
NASDAQ : Health Technology
Prev Close 99.27
Open 102.81
Day Low/High 99.22 / 106.30
52 Wk Low/High 84.45 / 278.62
Volume 822.51K
Avg Volume 419.60K
Exchange NASDAQ
Shares Outstanding 19.01M
Market Cap 1.88B
EPS 6.80
P/E Ratio 2.97
Div & Yield N.A. (N.A)
SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal...

Ligand Reports Third Quarter 2016 Financial Results

Ligand Reports Third Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2016, and provided an operating forecast and program updates.

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug...

Ligand Announces Third Quarter 2016 Earnings Release Date And Participation In The Stephens Fall Investment Conference

Ligand Announces Third Quarter 2016 Earnings Release Date And Participation In The Stephens Fall Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2016 financial results on November 3, 2016.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MENT Downgrades: ELS, FRBK, LGND, MOG.B, SXL, THC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ligand Partner Lundbeck Receives FDA Approval Of Carnexiv™ (carbamazepine) Injection As Intravenous Short-Term Replacement Therapy For Certain Seizure Types

Ligand Partner Lundbeck Receives FDA Approval Of Carnexiv™ (carbamazepine) Injection As Intravenous Short-Term Replacement Therapy For Certain Seizure Types

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Lundbeck announced today that the U.

Ligand Licenses Four Programs To Seelos Therapeutics

Ligand Licenses Four Programs To Seelos Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the licensing of rights to four programs to Seelos Therapeutics, Inc.

Ligand Enters OmniAb® License Agreement With TeneoBio, Inc.

Ligand Enters OmniAb® License Agreement With TeneoBio, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc.

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company's glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM).

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Here are Wednesday's top research calls, including upgrades for ConocoPhillips and DineEquity, and downgrades for Discover and Maxim.

Ligand To Participate In Two Upcoming Investor Conferences

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Morgan Stanley Global Healthcare Conference...

Short Interest Falls 11% For LGND

Short Interest Falls 11% For LGND

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 489,935 share decrease in total short interest for Ligand Pharmaceuticals Inc , to 3,981,742, a decrease of 10.96% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Results From Phase 1 Trials With Ligand's LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism

Results From Phase 1 Trials With Ligand's LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces that results from two Phase 1 clinical trials with LGD-6972, the company's investigational glucagon receptor antagonist, were published online in the August...

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a weak on high relative volume candidate

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.

Ligand Reports Second Quarter 2016 Financial Results

Ligand Reports Second Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates.

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc.

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "perilous reversal" (up big yesterday but down big today) candidate

Ligand To Report Second Quarter Results On August 4th

Ligand To Report Second Quarter Results On August 4th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2016 financial results on August 4, 2016.

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc.

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand.

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Stocks with insider trader activity include ATHN, LGND and ASPS

Ligand Reports First Quarter 2016 Financial Results

Ligand Reports First Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix ®.

TheStreet Quant Rating: C (Hold)